Current COVID boosters offer good protection against severe outcomes but less so against JN.1 The current COVID-19 boosters targeting the Omicron XBB.1.5 subvariant are still offering solid protection against infection, hospitalizations, and death, but are somewhat limited in efficacy against illnesses caused by the JN.1 subvariant, now the dominant strain in the United States, according to a research letter yesterday in the New England Journal of Medicine. CIDRAP

...

How a simulation is informing COVID-19 vaccine policy after our 'return to normal' As the saying goes "There is no such thing as normal" and this has been especially true after the pandemic. Medical Xpress

...

Now, there is a complex global situation where populations in different countries have unique hybrid immunity landscapes, born from a wide range of vaccination history and exposure history combinations.

In 2023, we needed to consider what hybrid immunity meant for booster vaccinations. And what different types of hybrid immunity meant for future vaccination strategies.

Data: Heart-failure patients have 82% better odds of living longer if vaccinated against COVID The first study of COVID-19 vaccine effectiveness in a large population of adult heart-failure patients suggests that vaccinated participants are 82% more likely to live longer than their unvaccinated peers, according to an analysis presented over the weekend at the Heart Failure 2024 scientific congress of the European Society of Cardiology (ESC) in Lisbon, Portugal. CIDRAP

...